SKL NP
Alternative Names: SKL-11197; SKL-NPLatest Information Update: 20 Jul 2015
At a glance
- Originator SK biopharmaceuticals; SK Life Science
- Developer SK Life Science
- Class Analgesics
- Mechanism of Action 12-lipoxygenase inhibitors; 15-lipoxygenase inhibitors; Calcium channel modulators; Hyperpolarisation activated cation channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 30 Jun 2015 Discontinued - Phase-II for Diabetic neuropathies in USA (PO)
- 01 Jun 2013 SK Life Science completes a phase II trial in Neuropathic pain (diabetic peripheral neuropathy) in USA (NCT01521598)
- 19 Feb 2013 SK Life Science completes enrolment in a phase II trial in Neuropathic pain (diabetic peripheral neuropathy) in USA (NCT01521598)